Rhenman & Partners Asset Management AB Decreases Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Rhenman & Partners Asset Management AB lowered its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 16.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 38,000 shares of the company’s stock after selling 7,270 shares during the period. Rhenman & Partners Asset Management AB owned approximately 0.11% of TransMedics Group worth $2,369,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of TMDX. Clear Creek Financial Management LLC purchased a new position in TransMedics Group in the fourth quarter worth $352,000. Vaughan Nelson Investment Management L.P. boosted its position in shares of TransMedics Group by 9.9% in the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company’s stock worth $22,547,000 after purchasing an additional 32,605 shares in the last quarter. Baillie Gifford & Co. grew its stake in TransMedics Group by 14.9% during the 4th quarter. Baillie Gifford & Co. now owns 269,836 shares of the company’s stock worth $16,824,000 after buying an additional 34,947 shares during the last quarter. State of Michigan Retirement System purchased a new position in TransMedics Group during the 4th quarter worth $6,734,000. Finally, Zacks Investment Management acquired a new position in TransMedics Group during the 3rd quarter valued at about $1,607,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Robert W. Baird lowered their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a research note on Wednesday, March 26th. Canaccord Genuity Group reiterated a “buy” rating and set a $104.00 price objective on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Piper Sandler dropped their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Trading Down 4.6 %

TransMedics Group stock opened at $67.67 on Friday. The firm has a market cap of $2.28 billion, a PE ratio of 71.99 and a beta of 2.14. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The stock’s 50 day simple moving average is $70.07 and its two-hundred day simple moving average is $85.74. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.